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In 2003 the World Health Organization (WHO) and the United 
Nations AIDS Organization (UNAIDS) launched a strategy 
to extend antiretoviral treatment (ART) to 3 million people 
living with HIV/AIDS in low- and middle-income countries 
by the end of 2005.1 As a result of this strategy there are now 
over 500 000 people on ART in sub-Saharan Africa, where the 
burden of disease is greatest. This reflects a 3-fold increase in 
the number of people receiving treatment in the region during 
the 12 months up to June 2005.2 With this dramatic expansion 
in services, concerns have been raised that expanding access 
to ART in resource-poor settings will lead to ‘antiretroviral 
anarchy’ characterised by poor adherence to therapy, 
widespread viral resistance to medications and ultimately poor 
clinical outcomes.3 
To date, a number of programmes have demonstrated the 
feasibility of providing ART services on a relatively small 
scale,4-10 and have shown that in these instances clinical and 
virological outcomes in these programmes parallel outcomes 
in Europe and North America.11,12 A recent article by Severe 
et al.13 makes an important contribution to the published 
literature on the scale-up of access to ART in resource-limited 
settings. The results of the first 1 000 patients treated in Port-
au-Prince, Haiti, with limited infrastructure and staff are 
remarkable compared with those from First-World settings. 
After 1 year of therapy, 87% of adults and 98% of children 
were still alive. An editorial in the same journal14 called for 
accelerated enrolment in both urban and rural settings. But 
despite the rapid expansion of ART services in sub-Saharan 
Africa, there are few documented experiences of how the 
expansion of ART services over time may affect their quality. 
As ART programmes increase the numbers of patients served, 
there are parallel increases in the burden on staff, affecting 
each category of health care provider. The increased burden 
on health providers associated with scale-up may result in 
reduced time, on average, spent in the care of each patient in 
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Background. Despite rapid expansion of antiretroviral therapy 
(ART) in sub-Saharan Africa there are few longitudinal data 
describing programme performance during rapid scale-up. 
Methods. We compared mortality, viral suppression and 
programme retention in 3 consecutive years of a public sector 
community-based ART clinic in a South African township. 
Data were collected prospectively from establishment of 
services in October 2002 to the censoring date in September 
2005. Viral load and CD4 counts were monitored at 4-monthly 
intervals. Community-based counsellors provided adherence 
and programme support.
Results. During the study period 1 139 ART-naïve patients 
received ART (161, 280 and 698 in the 1st, 2nd and 3rd years 
respectively). The median CD4 cell counts were 84 cells/μl 
(interquartile range (IQR) 42 - 139), 89 cells/μl (IQR 490 
- 149), and 110 cells/μl (IQR 55 - 172), and the proportions 
of patients with World Health Organization (WHO) clinical 
stages 3 and 4 were 90%, 79% and 76% in each sequential year 
respectively. The number of counsellors increased from 6 to 28 
and the median number of clients allocated to each counsellor 
increased from 13 to 33. The overall loss to follow-up was 2.9%. 
At the date of censoring, the Kaplan-Meier estimates of the 
proportion of patients still on the programme were 82%, 86% 
and 91%, and the proportion who were virally suppressed  
(< 400 copies/ml) were 100%, 92% and 98% for the 2002, 2003 
and 2004 cohorts respectively.
 Conclusions. While further operational research is required 
into optimal models of care in different populations across 
sub-Saharan Africa, these results demonstrate that a single 
community-based public sector ART clinic can extend care to 
over 1 000 patients in an urban setting without compromising 
programme performance.
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the service. Similar phenomena, with increases in patient load 
associated with reductions in programmatic success, have 
been documented in a number of other primary care services, 
including the diagnosis and management of tuberculosis and 
sexually transmitted infections.15-17 In this light it is possible 
that the good programmatic outcomes – including high rates 
of virological suppression and retention in services along with 
low mortality – that have been achieved by small, focused ART 
services, may be difficult to maintain as programmes grow in 
size. 
The question of how programmatic outcomes in 
antiretroviral services are influenced by rapid increases in 
patient load has significant implications for the scale-up of 
HIV care and treatment services in sub-Saharan Africa. While 
there is a wide range of different approaches to delivering ART 
services, there are few insights into the service delivery models 
that can best maintain optimal patient care and programmatic 
outcomes. For example, if programmes with large patient 
loads have difficulty maintaining the high levels of viral 
suppression and patient retention and low levels of mortality 
that can be achieved with smaller services, then multiple small-
scale services may be preferable to fewer, larger services for 
delivering ART to a specific population. Insights into these 
questions of programme expansion and optimal patient load 
are urgently required to inform health systems and policies for 
ART scale-up in resource-limited settings.
In this light, we reviewed changing patterns in virological 
outcomes, patient survival and programme retention among 
patients attending a public sector community-based ART 
programme in a South African township. The programme 
was established in September 2002 and rapidly expanded its 
services, enrolling 1 139 patients by October 2005.
Methods
Setting
Guguletu Clinic is situated in the urban Nyanga district of 
Cape Town, which has an estimated population of 350 000 
and is served by 10 primary care HIV clinics18 that comprised 
the patient referral base. The district is socially deprived 
with an estimated 57% unemployment rate and with 81% 
of households living in informal dwellings,19 a tuberculosis 
notification rate of 1 026/100 000,20 and an antenatal HIV-1 
seroprevalence rate of 28%, which is among the highest in the 
province.21 The Usapho Lwethu (Our Family) ART programme 
is a dedicated ART clinic based at the Guguletu Community 
Health Centre, Cape Town.22 A pilot programme was started 
in 2002 with funding support from an international donor, 
and the expansion of services in subsequent years has been 
supported by a grant from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria. 
ART programme
Enrolment into the programme follows the National Ministry 
of Health ART guidelines,23 which are based on the 2002 
WHO recommendations for scaling up ART in resource-poor 
settings.24 The medical criteria for adult ART eligibility include 
those with a prior AIDS diagnosis or a blood CD4 cell count  
< 200 cells/μl, and for children, paediatric stage III disease or a 
CD4 cell percentage < 20%.
Following referral from a primary care clinic, the standard 
schedule of visits was as follows: screening visit (week 0), 
screening blood tests (week 2), treatment initiation (week 4) 
and treatment follow-up (weeks 8, 12, and 20, and 16-weekly 
thereafter). At the screening visit, a treatment-readiness 
evaluation was completed and a 4-week supply of co-
trimoxazole was dispensed to patients with less than 200 
CD4 cells/μl, with pill counts at 14 and 28 days to assess 
adherence. Dapsone was used as an alternative for those 
with co-trimoxazole intolerance. Patients were assessed by 
a doctor for symptomatic HIV-associated disease. First-line 
ART comprised stavudine, lamivudine plus a non-nucleoside 
reverse transcriptase inhibitor (efavirenz or nevirapine). The 
second-line regimen comprised lopinavir/ritonavir, zidovudine 
and didanosine. A secure supply of medication was maintained 
by the local health authority throughout the study period and 
all treatment was supplied free of charge. In addition to the 
scheduled clinic appointments, patients had open access to the 
clinic for medical problems. 
Therapeutic counsellors
At the screening visit patients were allocated to a community-
based ‘therapeutic counsellor’ living in the Guguletu area. 
These community-based counsellors, the majority of whom 
are living with HIV/AIDS, provide ongoing counselling 
support, addressing psychosocial issues and reinforcing the 
need for high levels of treatment adherence. Counsellors were 
responsible for treatment-readiness group information sessions 
carried out twice weekly in a local community hall, clinic-
based adherence reinforcement sessions and home visiting.
Laboratory monitoring
Plasma HIV load and blood CD4 cell count were performed 
at week 2 and 4-monthly after commencing ART. Toxicity 
monitoring comprised a full blood count and liver function 
tests performed at week 2, and subsequently at 4-monthly 
intervals. All laboratory tests were performed on site by a 
single laboratory technician in a self-contained laboratory 
located in a modified shipping container. Plasma HIV-1 
load was measured using the Versant HIV-1 RNA 3.0 assay 
performed on a 340 bDNA analyser (Bayer Diagnostics, 
Tarrytown, NY, USA) with a lower limit of detection of 50 
RNA copies/ml. Blood CD4 cell counts were measured using 
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flow cytometry (Becton Dickenson FACSCount, New Jersey, 
USA). Internal quality assurance (QA) and interlab QA were 
performed for the viral load and CD4 measurements and 
full blood counts and CD4 measurements were subject to 
additional external QA.
Data sources
Structured clinical records were maintained on all patients 
screened on entry to the ART programme and this information 
together with laboratory results was regularly transferred 
to an electronic database. The Research Ethics Committee 
of the University of Cape Town approved the use of patient 
information from this service for programme evaluation, and 
as part of this, all enrolled patients gave written informed 
consent for anonymous clinical data to be recorded and 
analysed. 
Statistical analysis
Data were analysed using Stata version 9.0 (College Station, 
Texas, USA). Three annual cohorts were defined as patients 
initiating ART during the 12 months from 1 September 2002 
(the 2002/2003 cohort), 2003 (the 2003/2004 cohort) and 2004 
(the 2004/2005 cohort). The demographic profile and baseline 
immunological and virological characteristics of the cohorts 
were compared using Wilcoxon’s rank-sum and chi-square 
tests for medians and proportions, respectively; trends across 
annual cohorts were assessed using Cuzick’s non-parametric 
trend test for medians and Cochrane-Armitage tests for 
proportions. The retention of patients in the programme was 
compared across annual cohorts using Kaplan-Meier analyses 
with log-rank tests. All statistical tests are 2-sided at a = 0.05.
Results
Programme entry
During the first 3 years of the service, 1 510 patients were 
referred to the programme for ART, of whom 1 139 were 
commenced on treatment. Of the 371 not starting ART, 155 
(42%) did not meet entry qualifications or received therapy 
elsewhere, 146 (39%) were awaiting treatment initiation at the 
censoring date and 70 (19%) died before starting ART.  The pre-
ART death rate was 34.6/100 patient-years (confidence interval 
(CI): 27 - 43) and did not vary significantly between the annual 
cohorts. Recruitment increased steadily during the study 
period (October 2002 - September 2005), with greater numbers 
of children and pregnant women entering the programme in 
the second and third years (Table I). There was a significant 
trend for individuals recruited into the programme to have less 
advanced HIV in the second and third years as demonstrated 
by higher median CD4 count, lower log10 mean viral load 
and a lower proportion with an AIDS diagnosis (Table I). 
The proportion of pregnant women entering the programme 
who had AIDS was low (5%) compared with non-pregnant 
adults (30%). The CD4 count of children at programme entry 
(median 540 cells/μl, interquartile range (IQR) 244 - 906) was 
significantly higher than that of adults (101 cells/μl, IQR  
48 - 168). As further treatment sites were initiated elsewhere in 
South Africa, an increasing number of patients were transferred 
in and out of the programme on ART. 
Staffing and physical infrastructure
The programme commenced with a staff of 1 doctor, 1 nurse 
and 8 counsellors. At the end of the study period staffing 
Table I. Baseline characteristics of 1 139 patients starting ART between October 2002 and  
September 2005
2002/3 2003/4 2004/5 p-value
Number starting ART 161 280 698
Median age (yrs) 33 32 32   0.19
Age range (yrs) 7 - 58 1 - 54 1 - 64
Female (N (%)) 114 (74.5) 193 (75.7) 479 (65.4)   0.002
Pregnant at entry (N) 1 39 80   0.06
Children < 14 years (N) 1 3 69 < 0.001
Median CD4 (cells/μl (IQR)) 84 (42 - 139) 89 (49 - 149) 110 (55 - 172) < 0.001
Median log10 viral c/ml (IQR) 4.98 (4.58 - 5.33) 4.87 (4.50 - 5.23) 4.72 (4.25 - 5.14) < 0.001
WHO stage 4 (N (%)) 68 (44.4) 64 (25.1) 157 (21.5) < 0.001
WHO stage 3 (N (%)) 69 (45.1) 140 (54.9) 397 (54.2)
WHO stages 1 and 2 (N (%)) 16 (10.5) 51 (20.0) 178 (24.3)
Transfers in/out (N) 0/1 0/39 32/80
Died on treatment (N) 21 22 35
Lost to follow-up (N) 8 17 8
IQR = interquartile range.
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had increased to 4 doctors, 3 nurses, 1 pharmacist and 
28 counsellors (Fig. 1). There was a high turnover of the 
professional staff employed by the local provincial authority, 
with frequent use of temporary staff to provide services. In 
contrast, there was very low turnover of counsellors, who 
constitute approximately 80% of all staff employed by the 
programme. The number of clients allocated to each counsellor 
increased over time, with a median of 13, 19, and 33 patients 
per counsellor during 2002/3, 2003/4 and 2004/5, respectively. 
In terms of infrastructure, the ART service started in a single 
clinic room within the local health facility. Increasing patient 
numbers necessitated a move to an on-site prefabricated cabin 
in 2004 and to a self-contained building within the clinic 
grounds in 2005.
Programme retention
One hundred and one patients were lost to the programme, 
and 78 patients (7%) died after starting ART, with 63% of 
deaths occurring in the first 90 days of ART. 
Thirty-three patients (3%) were lost to follow-up during the 
study period. The Kaplan-Meier estimate of proportion lost to 
programme at 1 year did not differ significantly between the 3 
annual cohorts (Fig. 2).
Virological outcomes
The median proportions of viral loads < 400 copies/ml and  
< 50 copies/ml at all monitoring time points were 95% and 
82%. At the censoring date, the 2002/3, 2003/4 and 2004/5 
cohorts had 100%, 92% and 98% of viral loads < 400 copies/ml 
and 88%, 67% and 85% < 50 copies/ml respectively (Fig. 3, A 
and B). During the study period 21 patients had 2 consecutive 
viral loads > 1 000 copies/ml (6, 11 and 5 in each sequential 
annual period) and 17 patients were changed from first- to 
second-line regimen (6, 8 and 3 in each of the sequential annual 
periods). 
Discussion
This is one of longest-running public-sector community-based 
ART programmes in sub-Saharan Africa, allowing a unique 
assessment of trends during a period of increasing recruitment 
Fig. 1. The cumulative number of patients recruited onto the 
antiretroviral programme together with number of doctors, nurses and 
counsellors in each quarter-year period between October 2002 and 
September 2005. 
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to more than 1 000 patients at a single clinic.  On-treatment 
virological suppression rates were excellent, were sustained 
over the 3-year period and compare very favourably with 
other published treatment programme outcomes in Africa,4-10 
Europe and North America.25 These results show that key 
programmatic outcomes can be maintained during a period of 
rapid expansion of services.
While the experience of this programme in rapidly 
expanding services is encouraging, these results should be 
interpreted with the following caveats. Recruitment to the 
programme was restricted to individuals living within a 
demarcated urban catchment area. While this geographical 
proximity may be similar to that of other peri-urban townships 
where large populations access health care, this model 
may not be generalisable to rural and other settings where 
populations are more dispersed. Furthermore the median 
pre-ART period of follow-up was similar for each of the 
yearly cohorts and therefore pre-ART mortality rates could be 
compared.  However, the median on-ART follow-up varied 
and was shorter for the later cohorts. Therefore, while the 
short-term results were comparable, the long-term results seen 
in the 2003/4 cohort may not necessarily be achieved by those 
accessing therapy later.    
The low proportion of males together with the advanced 
clinical stage of non-pregnant adults accessing this programme 
is of concern, as this may be an indication that ART coverage 
is still inadequate at a population level. Patients generally 
accessed the programme when their disease was advanced, 
which is reflected by high mortality in the pre-ART and early 
treatment phase. The high mortality and morbidity of those 
who present with very advanced illness disproportionately 
utilises medical resources around the time of ART initiation.26 
Clinic recruitment could be increased if the programme were 
accessed earlier. There was a trend towards an increase in 
median CD4 cell count over the study periods, which was more 
marked in the third year. It would be encouraging if earlier 
presentation represented a decrease in the backlog of advanced 
HIV infection in the population; however the increase in 
median CD4 cell count was not paralleled by a decrease in pre-
ART mortality, which remained unacceptably high.  The higher 
median CD4 cell count was largely explained by an increase in 
non-traditional recruitment of pregnant women and children. 
Pregnant women were referred after accessing voluntary 
counselling together with CD4 cell count testing at the local 
maternal-obstetric service and had markedly less symptomatic 
HIV disease. The increasing number of children reflected an 
increase in collaboration with paediatric HIV services resulting 
in increased referrals from hospital-based specialist units to 
community care, and children had significantly higher baseline 
CD4 cell counts than adults. 
To date, physical infrastructure has not been identified as 
a key barrier to implementation of ART access in the context 
of small-scale services.27 However our experience has been 
that physical space is a critical constraint in the expansion of 
this programme, as the clinic had to be relocated twice in 3 
years, including the development of an off-site location for 
pre-treatment counselling. In addition, the positioning of a 
dedicated laboratory in a shipping container on site enabled 
an efficient monitoring service, avoiding the need for sample 
courier services and expediting access of results to medical 
staff. The on-site laboratory was economically viable when 
monitoring > 1 000 patients on ART (data not shown) and 
could be used for similar large single clinics or geographically 
clustered clinics in both urban and rural settings serving  
1 000 - 10 000 patients. An increasing number of patients were 
transferred from and to other treatment centres during year 3. 
As ART programmes mature there will be an increasing need 
for tracking systems, which can enable efficient transfer of 
patients between treatment centres.
Although programme acceptability was not specifically 
measured as part of routine clinical services, the low rate 
of loss to follow-up observed may reflect levels of client 
satisfaction. Shortage of human resources, in particular 
nurses, has been identified as a major operational constraint 
to treatment access.27 The specific model of care reported in 
this study was a dedicated ART community clinic, relying 
on a high ratio of lay counsellors to clients. The community-
based counsellors supplied continuity and served as the major 
conduit for ongoing interaction between the programme and 
clients. The allocation of a personal ‘therapeutic counsellor’ 
to each client on entry into the programme facilitated the 
high levels of treatment adherence (contributing to virological 
suppression rates) and retention in the programme. In contrast 
to the health professionals, they are readily accessible and 
their utilisation results in employment opportunities for 
individuals living with HIV/AIDS in a community with high 
unemployment.
In summary, this analysis of a community-based, public-
sector ART service demonstrates that a single urban public 
clinic can supply and monitor ART to more than 1 000 patients, 
without compromising programme performance during rapid 
scale-up. This finding bodes well for the expansion of ART 
services in resource-limited settings
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